Insider Selling: Orthofix Medical Inc. (NASDAQ:OFIX) CEO Sells $157,739.42 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,203 shares of Orthofix Medical stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the sale, the chief executive officer now directly owns 124,151 shares in the company, valued at approximately $2,127,948.14. This represents a 6.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 10th, Massimo Calafiore sold 10,078 shares of Orthofix Medical stock. The stock was sold at an average price of $16.83, for a total transaction of $169,612.74.

Orthofix Medical Price Performance

OFIX stock opened at $17.93 on Friday. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73. The firm has a 50 day moving average of $18.15 and a 200-day moving average of $16.76. The firm has a market capitalization of $685.11 million, a P/E ratio of -5.73 and a beta of 1.10. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

Wall Street Analyst Weigh In

OFIX has been the subject of several research reports. Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and increased their price objective for the company from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm reiterated a “buy” rating and set a $22.00 price target (up previously from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.00.

Institutional Investors Weigh In On Orthofix Medical

A number of large investors have recently made changes to their positions in OFIX. Franklin Resources Inc. boosted its position in shares of Orthofix Medical by 37.4% in the 3rd quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company’s stock worth $337,000 after purchasing an additional 5,702 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Orthofix Medical in the second quarter worth approximately $832,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Orthofix Medical by 14.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company’s stock valued at $5,073,000 after purchasing an additional 39,901 shares during the last quarter. AYAL Capital Advisors Ltd boosted its holdings in Orthofix Medical by 10.2% in the second quarter. AYAL Capital Advisors Ltd now owns 686,794 shares of the medical device company’s stock worth $9,107,000 after purchasing an additional 63,697 shares during the last quarter. Finally, Barclays PLC raised its stake in Orthofix Medical by 38.8% during the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company’s stock valued at $1,912,000 after buying an additional 34,210 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.